Clinical trial NCT01783132: Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home
Official title: Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Asthma
Lead sponsor: Orion Corporation, Orion Pharma
Sponsor class: INDUSTRY
Collaborators: name: Aerocrine AB
First posted: 2013-02-04
Enrollment: 142
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: SOC
Primary purpose: PREVENTION

Brief summary: To compare the clinical outcome (effectiveness) of single inhaled corticosteroid (ICS) controller treatment guided by exhaled NO measurement made at home with usual care asthma management with regard to asthma control (primary outcome), asthma-related quality of life, lung function, airway inflammation, medication use, and asthma events.

To understand changes in patient behaviour triggered by daily FENO measurement at home, for example treatment adherence and voluntary allergen exposure.

Detailed description: The design is a pragmatic randomized controlled, open-label, parallel group study Screening visit 1 and visit 2 is separated with a 2-4 week run-in period. At screening visit, Informed Consent is signed and atopic asthma confirmed, spirometry is performed and questionnaires responded to. At visit 2 venous blood samples are taken and serum stored at -20 °C for later transport to Uppsala Biobank, Exhaled NO is measured at both visit using NIOX MINO (blinded in control group).

* The active group if on combination inhaler, will switch to Giona Easyhaler (same budesonide equivalent as before study entry) and Oxis (same formoterol equivalent as before study entry). These patients will receive a NIOX MINO and will be taught about the adjustment of ICS treatment according to daily exhaled NO measurement at home and a personalized treatment algorithm.
* The control group will stay on previous controller treatment (only changed if indicated by symptoms at visit) according to usual care.
* Both groups will switch short-acting beta-2-agonist to Buventol Easyhaler.
* Both groups will report symptoms (ACQ) monthly and in connection to asthma events via an ePRO system (ViedocMe, PCG). Active group will report NO values on a weekly basis via the same system.

There will be a follow-up clinic visit 3 at 6 months with exhaled NO measurement (blinded in control group) and limited set of questionnaires. A second follow-up visit 4 at 12 months with exhaled NO, spirometry, full set of questionnaires and blood sample will be made.

Eligibility criteria: Inclusion Criteria:

* Age ≥18, ≤64 years
* Physician-diagnosis of asthma
* Regular inhaled budesonide (Giona Easyhaler, Pulmicort Turbuhaler, Novopulmon Novolizer or Symbicort Turbuhaler) treatment since at least 6 months
* Verified allergy to at least one airborne perennial allergen after objective testing (ImmunoCAP Rapid Asthma/Rhinitis Adult)
* ACQ \>1.0
* Can read and understand the Swedish language
* Written informed consent signed

Exclusion Criteria:

* Regular tobacco use within past 6 months
* ≥10 pack-years smoking history
* Keeping a furred pet at home
* Treatment with Singulair
* \>4 prednisolone courses last 12 months
* Ongoing pregnancy or lactation
* Participation in another clinical trial

Primary outcomes:
measure: Asthma symptoms in correlation to grade of inflammation in airways
timeFrame: Up to 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Uppsala
country: Sweden
facility: Lungkliniken, Universitetssjukhuset i Uppsala
Study officials:
affiliation: Aerocrine AB
name: Kjell Alving, Dr
role: STUDY_DIRECTOR
References: